Neisseria meningitidis (Nm) and N. gonorrhoeae (Ng) express a Macrophage Infectivity Potentiator (MIP, NMB1567/NEIS1487) protein in their outer membrane (OM). In this study, we prepared independent batches of liposomes (n = 3) and liposomes + MonoPhosphoryl Lipid A (MPLA) (n = 3) containing recombinant truncated Nm-MIP protein encoded by Allele 2 (rT-Nm-MIP, amino acids 22-142), and used these to immunize mice. We tested the hypothesis that independent vaccine batches showed similar antigenicity, and that antisera could recognise both meningococcal and gonococcal MIP and induce cross-species bactericidal activity.
Introduction
Neisseria meningitidis (Nm, Men, meningococcus) is a major causative organism of meningitis and sepsis contributing significantly to mortality and morbidity worldwide [1] , and Neisseria gonorrhoeae (Ng, gonococcus) causes the sexually transmitted disease gonorrhoea [2] . Capsular polysaccharideconjugate vaccines to prevent infections by MenA, MenC, MenW and MenY meningococci are widely available, routinely used and effective [3, 4] , and two new vaccines Bexsero and Trumenba, have been licensed for MenB infection [5, 6] . Bexsero has shown a vaccine efficacy of 83% against all MenB cases in vaccine-eligible infants in the UK since 2015, equivalent to $94% efficacy against the 88% predicted vaccine-preventable MenB strains [7] . A 50% reduction in MenB cases was observed in the vaccine eligible https://doi.org/10.1016/j.vaccine.2018.05.069 0264-410X/Ó 2018 Published by Elsevier Ltd.
age-group, which seems to have persisted [8] . By contrast, there are no gonorrhoea vaccines and infection control has relied on antibiotics, but this is being severely compromised by the emergence of antibiotic-resistant gonococci worldwide [9] . Thus, new vaccine technologies have led to renewed interest in developing prophylactic gonococcal vaccines [10, 11] .
The impact of new MenB vaccines on the levels of protection, the epidemiology of circulating meningococcal strains, the potential for selection of new antigenic variants and variation in protein expression, needs to be monitored. Next-generation MenB vaccines may see the incorporation of additional antigens capable of inducing serum bactericidal antibodies, the accepted correlate of protection. A possible candidate for inclusion in new vaccines is the Macrophage Infectivity Potentiator protein (MIP, NMB1567/ NEIS1487), which is a member of the FK506-binding protein (FKBP)-type peptidyl prolyl cis/trans isomerase (PPIase) family of proteins [12, 13] . Expression of the nm-mip gene was important for meningococcal survival in the blood [13, 14] and inhibition of Nm-MIP prevented meningococci from adhering, invading and/or surviving in epithelial cells [15] . Nm-MIP is highly conserved and expressed by all meningococcal strains reported to date, is outer membrane (OM)-located, surface exposed and capable of inducing cross-protective bactericidal antibodies [13, 16, 17] . N. gonorrhoeae also produces a FKBP-type PPIase and expression of the surfaceexposed 30 kDa Ng-MIP lipoprotein appeared to be important for bacterial persistence within macrophages and protected gonococci from the bactericidal activity of immune effector cells [18, 19] . Sera from patients with urethritis or disseminated gonococcal infections recognized purified Ng-MIP, suggesting that this antigen is expressed during infection in vivo and is immunogenic [13, 18, 19] . Ng-MIP is also highly conserved across all reported strains of N. gonorrhoeae, although the vaccine potential has not been reported.
Recently, we reported that Nm-MIP and human FKBP2 PPIase protein shared $48% similarity of amino acids (AA) located in region AA166-252. The C-terminal globular domain of Nm-MIP covers AA143-272 and contains the PPIase FKBP-type domain [16] . Molecular mimicry between Nm-MIP with hFKBP2 protein was obviated by generating a recombinant truncated protein (rTNm-MIP, AA22-143), which induced murine bactericidal antibodies against meningococci that did not recognise human FKBP protein [16] . A baby rabbit complement Serum Bactericidal Assay (BRC-SBA) demonstrated that antibodies to rT-Nm-MIP Type I protein were bactericidal for MenB bacteria expressing different MIP (Type I, II and III) proteins and for MenA, MenC, MenW and MenY bacteria expressing the same MIP protein. Antisera to rT-Nm-MIP appeared also to show bactericidal activity against a gonococcal strain P9-17, although the BRC-SBA showed high levels of background killing by sham-immunized sera. For examining bactericidal activity of antisera raised to recombinant proteins, it is preferable that MenB and gonococcal SBAs use a human complement/human serum (HC/HS) source rather than BRC, which tends to inflate bactericidal titres due to the presence of IgM antibodies. It has been reported also that the HC-SBA is conservative with a high rate of false-negatives, which makes the assay less sensitive, but more specific, that the BRC-SBA [20] [21] [22] .
In the current study, we extended our studies of the vaccine potential of rT-Nm-MIP by (i) examining the antigenicity of independent batches of experimental vaccines against meningococci and gonococci, (ii) using HC/HS-SBA assays to quantify bactericidal activity against meningococci and gonococci expressing different MIP Type proteins and (iii) attempting to engineer the MenB OM to express truncated MIP.
Materials and methods

Bacteria, growth conditions and preparation of outer membranes (OM)
Bacteria used in this study are listed in Table 1 . Wild type and mutant strains were grown on supplemented GC agar plates, incubated at 37°C, 5% (v/v) CO 2 [23] . For human complementmediated serum bactericidal assays (HC-SBA), N. gonorrhoeae strains MS11 and 12CFX_T_003 were grown on supplemented GC agar plates with the addition of Cytidine-5 0 -MonoPhospho-N-Acet ylNeuraminic Acid to impart resistance to human serum (HS) [24] . Escherichia coli DH5a (cloning) and BL21(DE3) pLysS strains (protein expression) were grown at 37°C on Luria-Bertani (LB) agar, LB or SOB broths.
OM of MC58, MC58Dmip and MC58Dmip::t-nm-mip, P9-17 and FA1090 bacteria were prepared as described previously [25, 26] . Treatment with sodium deoxycholate (Na-DOC) was done as described previously [26] .
Construction of Neisseria meningitidis nm-mip gene and Neisseria gonorrhoeae ng-mip gene knock-out mutants
Construction of MC58Dmip, FA1090Dmip and P9-17Dmip mutant strains was done as described previously [14, 16] using primers listed in Supplementary Table 1 . Transformed colonies were screened by PCR and confirmed by western blotting using crossreacting rabbit anti-rNm-MIP sera [17] .
Complementation of MC58Dnm-mip strain with c-term truncated nm-mip
For chromosomal complementation of MC58Dmip strain, the 3 0 -end truncated nm-mip gene (encoding for AA1-143) under transcriptional regulation of a strong and constitutive PorA/NadA hybrid promoter [27] was engineered in silico into pMA-T (GeneArt) and subsequently cloned into pGCC5. This construct was used to complement MC58Dmip strain [28] . Positive transformants were identified by PCR screening and western blotting with rabbit anti-rNm-MIP sera [17] .
2.4. Cloning, expression, and purification of recombinant full and TNm-MIP (M2, Type I) proteins
Cloning, expression and purification of full-length rNm-MIP (M2, Type I) protein was described previously [17] . The 3 0 -truncated nm-mip gene sequence, encoding the N-terminal amino acid sequence (AA 22-143) for NMB1567 protein (NEIS1487, http://pubmlst.org/neisseria/, 819 bp), was amplified by PCR using primers listed in Supplementary Table 1 , and ligated to pET24b+. Mature M2 (Type I) rT-Nm-MIP protein (13.93 kDa) was purified by Ni-NTA affinity chromatography under native conditions (Supplementary Fig. 1 ). 3 , following the immunization schedule described previously [16] . All sera were stored at -20°C until required and decomplemented by heating at 56°C for 30 min before use in HC/HS-SBA. This study complied with the animal experimentation guidelines of the Home Office (HO), with approval granted under the Animals Scientific Procedures Act, 1986 (HO PPL 3003126). The study was approved by the Animal Welfare and Ethics Review Board at the authors' institution (no number assigned). Animal health and welfare was assessed daily by qualified animal technicians and no animals suffered significant adverse effects. Individual murine antisera were reacted with M2 rT-Nm-MIP, MC58, MC58Dmip, MC58Dmip::t-nm-mip, N. gonorrhoeae P9-17 and FA1090 OM preparations. Immunological reactivity was detected with anti-mouse immunoglobulin-horseradish peroxidase conjugate, as described previously [16, 17] .
Animal immunizations
SDS-PAGE and western immunoblotting
Immunological reactivity of murine sera to OM preparations was detected with anti-mouse/rabbit immunoglobulin-alkaline phosphatase conjugates, as described previously [16, 17] .
Flow cytometry
Binding of antibodies to MC58, MC58Dmip, MC58Dmip::t-nmmip, P9-17, P9-17Dmip, FA1090 and FA1090Dmip bacteria was examined by flow cytometry, as described previously [16, 17] .
Complement-activated killing of Neisseriae
To prepare human complement (HC) source, 2.5 ml of fresh normal HS with the addition of 50 ml of 0.5 M EDTA, pH 8 and 350 ml of 5 M NaCl was incubated first with anti-human IgM resin and then with Protein A/G Plus resin (with rotation) at 4°C for 1 h each. The final HC eluate was dialyzed twice against filter-sterilized ice-cold TBS, 0.1 mM EDTA and brought back to 2.5 ml in the same buffer. The bactericidal activity of pooled murine anti-rT-Nm-MIP sera was determined as described previously [29] , using 25% (v/v) HC for meningococcal strains [22, 30] and 17% (v/v) HS as a source of exogenous complement for gonococcal strains [31] .
Statistics
Data were compared using one-sample, two-sample or paired tTests, as appropriate, with P values < 0.05 considered significant.
Results
Conservation of NEIS1487 in pathogenic Neisseria species
The DNA sequences of the nmb1567/neis1487 gene from pathogenic Neisseria strains in the pubmlst.org/Neisseria database [32] were translated to amino acid sequences and aligned. The database contains 10,434 meningococcal and 3876 gonococcal isolates (accessed Jan. 2018) with 168 and 33 alleles identified, respectively. Analysis of the translated proteins encoded by the nucleotide sequences of these different alleles identified 75 and 18 nonredundant NEIS1487 amino acid sequences amongst meningococci and gonococci respectively (Supplementary Table 2 ; Supplementary Figs. 2, 3). The percentage distribution of meningococcal isolates amongst the non-redundant alleles has not changed significantly since a previous analysis [13] , with the majority expressing protein encoded by Allele 2 (41%), Allele 1 (32%) and Allele 7 (11%). For gonococci, most isolates expressed protein encoded by Allele 10 (59%) or Allele 35 (27%) and fewer isolates by other alleles e.g. Allele 8 (5%) (Supplementary Table 2 ). Only Allele 10 and 63 were found in both meningococci and gonococci ( Supplementary Fig. 3 ), though only 5 gonococcal isolates expressed Allele 63-encoded protein compared to a total of 115 meningococcal isolates, and conversely only 2 meningococcal isolates (not determined) expressed Allele 10-encoded protein compared to 2274 gonococcal isolates (Supplementary Table 2 ).
The MIP Type designation scheme was originally based on the isolate frequency for each non-redundant protein, referred to as Types I-IV, with Type I being the most abundant Type protein within all N. meningitidis isolates reported [13, 17] . We now reassign the MIP Type designation by referring to the representative allele encoding for a particular non-redundant MIP protein, thus becoming independent of the isolate frequency ranking for each particular MIP type, which varies as the database grows in number of isolates reported. Thus, in meningococci, M (i.e. MIP)2 protein is encoded by Allele 2 (formerly Nm-MIP Type I), M1 protein is encoded by Allele 1 (formerly Nm-MIP Type II), M6 protein is encoded by Allele 6 (formerly Nm-MIP Type III) and M7 protein is encoded by Allele 7 (formerly Nm-MIP Type IV) [13] and in gonococci, M8, M10 and M35 proteins are encoded by Alleles 8, 10 and 35, respectively (Supplementary Table 2 ).
Alignment of the amino acid sequences of the most prevalent meningococcal (M1, 2, 6, 7) and gonococcal (M8, 10, 35) alleleencoded proteins showed a high degree of homology between the whole proteins (97-99%, Fig. 1 ). Within the C-terminal truncated region, homology between the gonococcal sequences and M2 was 98-99% and marginally more variability between the different meningococcal sequences (96-99%) ( Supplementary Fig. 4 ).
Antigenicity of rT-Nm-MIP vaccine batches
The batch consistency of M2 rT-Nm-MIP-liposome (n = 3) and M2 rT-Nm-MIP-liposome + MPLA (n = 3) vaccines was assessed initially by testing individual antisera in ELISA against the immunizing protein, homologous MC58 OM, and OM from a MC58 mip knock-out strain that was engineered to constitutively express the mip gene fragment encoding the truncated protein without the 6 Â HIS tag (AA22-143). High titres of antibodies, reactive with homologous immunizing protein, were induced by rT-Nm-MIP in all six liposomal preparations ( Fig. 2A) , and no significant differences between the mean antibody titres was observed (mean $2.6 Â 10 6 , range 0.6 Â 10 6 -1.2 Â 10 7 , P > 0.05). These antibodies also reacted with homologous OM (Fig. 2B ) and the engineered rT-Nm-MIP-OM (Fig. 2C) , with similar titres observed ($0.37-0.67 Â 10 6 , P > 0.05) with all the immunizing preparations tested against both OM preparations. Notably, antisera to all the rT-Nm-MIP-liposome and rT-Nm-MIP-liposome + MPLA vaccines showed strong cross-reactivity with N. gonorrhoeae P9-17 ( , not significantly different (P > 0.05) from those observed on meningococcal OM. No significant reactivity (P > 0.05) was observed for any antiserum against MC58Dmip, P9-17Dmip or FA1090Dmip OM preparations (data not shown).
The specificity of the immune response against rT-Nm-MIP protein was demonstrated by western blotting. Pooled antisera of the independent batches of rT-Nm-MIP-liposomes and rT-Nm-MIP-li posomes + MPLA vaccines showed strong and similar reactivity with a single band of molecular mass (Mr) $29 kDa on MC58 OM (Fig. 3A) or $14 kDa (Fig. 3C ) on MC58Dmip::t-nm-mip OM. Specificity was confirmed by the lack of reactivity of any of the antisera with MC58Dmip mutant OM preparation (Fig. 3B) . These antisera showed cross-reactivity with gonococci, specifically recognising a single band of Mr $ 29 kDa on western blots of P9-17 ( Fig. 3D) and FA1090 (Fig. 3F) lysates. Specificity was confirmed by the lack of reactivity of any of the antisera with P9-17Dmip (Fig. 3E) or FA1090Dmip (Fig. 3G ) mutant strains. (Fig. 4) . Antisera crossreacted similarly with Ng-MIP on the surface of live P9-17 and FA1090 gonococci. Specificity was confirmed by the lack of reactivity (P > 0.05) of all murine post-immune sera with MC58Dmip, P9-17Dmip or FA1090Dmip strains (Fig. 4) .
Murine antibodies to rT-Nm-MIP are bactericidal for meningococci and gonococci
Using the HC-SBA, murine antisera raised to M2 rT-Nm-MIP were bactericidal for the homologous strains MC58 and MC168 with median titres of 32-64 for the rT-Nm-MIP-liposome preparations and 128-256 for the rT-Nm-MIP-liposome + MPLA preparations (Table 2 ). Specificity was demonstrated by the inability of antisera to kill the isogenic MC58Dmip strain. Antisera to M2 (Table 2) . By contrast, no killing was observed for any of the three MenB strains expressing M6 Nm-MIP protein. Of the two MenB strains that expressed M7 protein tested, one (M16 240169) was killed by antisera to rT-Nm-M IP-lipsomes + MPLA at low levels (titres 4-8), whereas the other (M15 240139) was not killed. For meningococci expressing homologous M2 protein but different serogroup capsule, significant killing was observed against MenC and MenW bacteria ( Table 2 ). For MenC, rT-N m-MIP-liposomes + MPLA antisera were bactericidal with a titre of 16; for MenW, rT-Nm-MIP-liposomes and rT-Nm-MIP-lipo somes + MPLA antisera showed bactericidal titres of [8] [9] [10] [11] [12] [13] [14] [15] [16] . By contrast, no significant bactericidal effect was observed for MenA or MenY bacteria (Table 2 ). It is possible that variation in surface expression of M2 protein accounted for the differences in bactericidal activity observed between these different serogroup meningococci. However, FACS analyses showed no significant differences (P > 0.05) of surface expression of M2 protein in the MenA, MenB, MenC, MenW and MenY isolates (Fig. 5) .
Using HS-SBA, antisera to M2 rT-Nm-MIP-liposomes and M2 rTNm-MIP-liposomes + MPLA also showed significant bactericidal activity against gonococcal strain P9-17 that expressed M35 protein, with titres of 64-128 and 64-512, respectively (Table 2) . Specificity was shown by the inability of any antisera to kill the isogenic P9-17Dmip strain (Table 2 ). Murine antisera also killed one strain expressing M10 protein, 12CFX_T_003 (titres 8-16), but not another, MS11. No killing was observed for strain FA1090, which expressed the M8 protein (Table 2) .
Expression of a truncated-Nm-MIP protein in the meningococcal OM
An alternative strategy for presentation of truncated Nm-MIP protein was attempted. A MC58 Dmip strain was designed to over-express constitutively M2 T-Nm-MIP protein under the transcriptional control of a hybrid, strong PorA/NadA promoter, and lipooligosaccharide (LOS)-reduced OM then produced. The lpxA gene could not be knocked-out in a MC58Dmip strain or the complemented MC58Dmip::t-nm-mip strain, using either piliated and non-piliated (non-naturally competent) N. meningitidis transformation methods [33] . Instead, LOS was extracted from wild-type MC58, MC58Dmip and MC58Dmip::t-nm-mip bacteria with Table 2 Bactericidal activity of pooled antisera against rT-Nm-MIP (M2) protein delivered in different liposomes formulations. The titres are expressed as the reciprocal of the highest dilution at which 50% killing was observed. Human complement (HC, 25% [v/v]) or normal human serum (HS, 17% [v/v]) were used as exogenous complement sources for meningococcal and gonococcal strains, respectively. Data are the median values, with the range of values in parentheses, for HC-SBA from 3 to 4 independent measurements of bactericidal activity of all pooled serum samples. Single values denote that the HC-SBA titres from the independent experiments were identical. Significantly high bactericidal activities relative to the corresponding controls are highlighted in red. Sera from sham-immunized mice (controls) and normal mouse serum (NMS) showed no significant bactericidal activity. Strains MS11 and 12CFX_T_003 are serum sensitive. ND, not determined. Fig. 5 ). However, western blotting ( Supplementary Fig. 6 ) and mass spectrometry analysis (data not shown) of the native OM, Na-DOC OM and all corresponding washes throughout the extraction process, demonstrated high solubility of full-length mature and truncated Nm-MIP proteins in Na-DOC that resulted in a significant loss of target antigen from within the OM.
Reciprocal
Discussion
The major findings from the current study were: (1) different batches of rT-Nm-MIP protein in liposomes and liposomes + MPLA showed no significant batch-to-batch variation in antigenicity; (2) the antibodies induced reacted specifically with Nm-MIP and Ng-MIP in their OM preparations and bound equally and specifically to live meningococcal and gonococcal cell surfaces; (3) use of HC/HS-SBA demonstrated that antisera to rT-Nm-MIP preparations killed meningococci and were cross-protective against gonococci, but there was significant divergence in bactericidal responses between different strains; (4) meningococcal OM were engineered to express T-Nm-MIP constitutively and at high levels as an alternative to recombinant protein production, but the use of Na-DOC for LOS extraction was contra-indicated.
Previously, we demonstrated using the BRC-SBA that antisera to M2 rT-Nm-MIP (Type I) protein were bactericidal against the (i) homologous MenB strain, (ii) heterologous MenB strains expressing M1 (Type II) and M6 (Type III) proteins and (iii) heterologous MenA, MenC, MenW and MenY bacteria expressing homologous M2 Nm-MIP [16] . However, the HC-SBA assays used in the current study demonstrated that the bactericidal responses and the levels of cross-protection determined with the previous BRC-SBA were over-estimates. Thus, no cross-protective bactericidal activity was observed against M6-expressing strains, or against MenA or MenY bacteria expressing homologous M2 Nm-MIP protein. Against strains expressing M7 (Type IV) protein, the bactericidal activity levels were marginal. For the gonococcal strains tested, bactericidal activity was observed for P9-17 (M35 Ng-MIP) and one strain 12CFX_T_003 (M10 Ng-MIP) but not for a strain expressing M8 Ng-MIP.
The lower bactericidal responses observed with the HC-SBA are consistent with the use of the more stringent complement source [20] [21] [22] . Although the N-terminal region of MIP is wellconserved, we examined whether the specific amino acid residue differences influenced bactericidal activity. Marginal levels of killing were observed for meningococci expressing M7 protein, which showed a deletion (amino acid residues 28-31) and a Ser39Ala change, compared to M2 protein (Fig. 4) . However, these are also the only two changes in N-terminal M1 protein, and meningococci expressing this type were killed, suggesting that these changes did not influence bactericidal activity with the M7-expressing strain. By contrast, Asp123 residue, which is conserved in all of the protein types, is changed to a Glu only in the M7 type protein and therefore may be important for bactericidal activity. Meningococci expressing M6 protein type were also not killed. In this protein, Ala140 and Asp142, which are conserved in the N-terminal domain of all of the other protein types, is changed to a Gly and Glu residue, respectively. Therefore, it is possible that the Ala140 and Asp142 residues are important for inducing bactericidal antibodies. We examined also the differences in amino acid sequences in the gonococcal MIP protein types, compared to meningococcal M2. In our study, gonococcal isolates expressing both M10 and M35 proteins were killed. The N-terminal domains of both proteins were identical with the only three changes being Ser39Ala, Ser49Gly and Glu83Asp (Fig. 4) . Surprisingly, gonococci expressing M8 protein, which also has the Ser39Ala and Glu83Asp substitutions, was not killed. Taken together, these observations suggest that these three amino acid residues are not important for the bactericidal response. It is possible that PorinB-mediated serum resistance imparted by binding of complement proteins and factor H [34] prevented the bactericidal activity of M2 rT-Nm-MIP antiserum, instead of these amino acid sequence differences. However, a limitation of the current study is that significantly larger numbers of isolates should be tested to confirm these findings.
Unexpectedly, there was variation in bactericidal activity of antisera to M2 rT-Nm-MIP tested against M2-expressing meningococci of different serogroups. Differential surface expression of Nm-MIP was not a factor (Fig. 5 ), suggesting several hypotheses: i) MenA and MenY capsules could hinder antibody binding to surface-exposed OM antigens, perhaps associated with capsule structure and density and ii) MIP could be masked by other surface molecules, e.g. other OM proteins and/or different terminal extensions of lipooligosaccharide such as the presence of phosphoethanolamine, enhancing serum-resistance [34] .
The most effective vaccine formulation was rT-Nm-MIPliposomes + MPLA, which increased bactericidal titres compared with rT-Nm-MIP-liposomes, albeit by only a factor of 2-4-fold. Several strategies could be considered for improving the immune response to the truncated protein. These would include testing a broader range of adjuvants and using methods to increase antigen density, e.g. by generating fusion proteins, in a manner described with Bexsero antigens [35] or by using virus-like particles [36] to present multiple truncated MIP sequences.
A recent epidemiological study suggested that vaccination with the MeNZB OMV vaccine in New Zealand was associated with statistically significant reduction in the rates of gonorrhoea diagnosis, with an estimated effectiveness of the vaccine against gonorrhoea of 31% [37] . This important observation suggests that meningococcal and gonococcal OM probably share common antigens, including MIP [13] , which may contribute to cross-protection. Therefore, engineering Nm-OMV vaccine(s) to express MIP and other proteins that cover the majority of meningococci and gonococci circulating in the populations, is a strategy that could be investigated. In the current study, we were able to engineer successfully the Nm-OM to express M2 Truncated -Nm-MIP constitutively and at high levels. However, LOS-extraction with Na-DOC was contraindicated, as it led to loss of the majority of T-Nm-MIP from the OM. Thus, future studies to engineer the OM to contain T-Nm-MIP should avoid the use of detergents and consider other genetic approaches to detoxify native LOS [38] .
Conclusion
Neisseria MIP proteins are potential targets for drug therapies during infection [15] and for the development of prophylactic vaccines [13] . Our data demonstrate the reproducibility of independent vaccines batches for generating bactericidal antibodies against a panel of homologous and heterologous MIP Type and serogroup meningococci, and cross-reactive with some gonococcal strains. The data suggest that the vaccine potential of truncated Ng-MIP proteins should also be examined and that a multicomponent vaccine containing a select number of Nm-and Ng-MIP type proteins would be required to provide broad coverage of both pathogens.
